Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track REGN with free AI briefings, catalyst countdowns, and dilution alerts.

REGN · Regeneron Pharmaceuticals, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$18.9B Cash on Hand
CF+ Cash Runway
2.3% Short Interest
$990.81 Analyst Target (27)
Follow REGN by email Get an email when REGN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about REGN, unsubscribe in one click. Privacy

📣 What REGN Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Dupilumab
FDA approved Mar 2017 · Dupixent
Atopic Dermatitis Phase 4 · NCT05268107 Recruiting
Pozelimab
FDA approved Aug 2023 · Veopoz
Age-related Macular Degeneration (AMD) Phase 3 · NCT06541704 Recruiting
Cemiplimab
FDA approved Sep 2018 · Libtayo
Melanoma Phase 3 · NCT06246916 Recruiting
Freneslerbart Allergic Conjunctivitis Phase 3 · NCT07675811 Recruiting
Mevonlerbart Allergic Conjunctivitis Phase 3 · NCT07675811 Recruiting
Mibavademab Monogenic Obesity Phase 3 · NCT07220772 Recruiting
Aspirin Symptomatic Venous Thromboembolism (VTE) Phase 3 · NCT07213778 Recruiting
Odronextamab Follicular Lymphoma (FL) Phase 3 · NCT06091254 Recruiting
Lipid Nanoparticle Encapsulating mRNA Encoding… Neuromuscular Disease Phase 3 · NCT06672237 Active not recruiting
Prednisolone Follicular Lymphoma (FL) Phase 3 · NCT06091254 Recruiting
REGN-2Cat Allergic Conjunctivitis Phase 3 · NCT07675811 Recruiting
Cenvacibart (REGN7508) Peripheral Artery Disease (PAD) Phase 3 · NCT07318610 Recruiting
Amrecibart (REGN9933) Peripheral Artery Disease (PAD) Phase 3 · NCT07318610 Recruiting
Vincristine Follicular Lymphoma (FL) Phase 3 · NCT06091254 Recruiting
Fianlimab Melanoma Phase 3 · NCT06246916 Recruiting
Bendamustine Follicular Lymphoma (FL) Phase 3 · NCT06091254 Recruiting

Also used in these trials (approved or third-party drugs, not REGN's own candidates): Pomalidomide, Gemcitabine Hydrochloride, Lenalidomide, Linvoseltamab, Paclitaxel, Pembrolizumab, Pemetrexed Disodium, Prednisone, Ravulizumab, Relatlimab, Rituximab, Rivaroxaban.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

REGN holds $18.9B in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when REGN files for a raise →

👥 Who Owns REGN

Insiders 2.2% Institutions (2032 holders) 92.6% Public and other holders 5.2%
HolderTypeShares% of sharesAs of
Blackrock Inc. Institution (13F) 8,849,583 9.42% 2026-09-30
Vanguard Capital Management Institution (13G, 5%+) 7,660,810 8.15% 2026-03-31
State Street Corporation Institution (13F) 4,881,362 5.20% 2026-09-30
Dodge & Cox Inc. Institution (13F) 4,774,489 5.08% 2026-09-30
Invesco Ltd. Institution (13F) 3,721,270 3.96% 2026-09-30
JPMORGAN CHASE & CO Institution (13F) 3,307,392 3.52% 2026-09-30
Vanguard Portfolio Management LLC Institution (13F) 3,111,677 3.31% 2026-09-30
Franklin Resources, Inc. Institution (13F) 2,950,805 3.14% 2026-09-30
Franklin Templeton, Inc. Institution (13F) 2,950,805 3.14% 2026-09-30
Geode Capital Management, LLC Institution (13F) 2,632,826 2.80% 2026-09-30
Nuveen, LLC Institution (13F) 1,955,949 2.08% 2026-09-30
George Yancopoulos
Bd. Co-Chair, President & CSO, Director · +595,077 options
Insider 1,125,945 1.20% 2025-12-31

Share count 93,955,110 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-11-04
filed 2026-11-06
Pitofsky Jason
Option exercise (M) 1,500 $726.53 5,772
2026-11-04
filed 2026-11-06
Pitofsky Jason
Option exercise (M) 1,500 – –
2026-11-04
filed 2026-11-06
Pitofsky Jason
Option exercise (M) 1,478 – –
2026-11-04
filed 2026-11-06
Pitofsky Jason
Option exercise (M) 905 – –
2026-11-04
filed 2026-11-06
Pitofsky Jason
Sale (S) 179 $950.76 0

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full REGN picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for REGN and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.